Incomplete Inhibition of Platelet Secretion by Low-dose Aspirin

Area of Science:

• Pharmacology
• Cardiovascular Research
• Hematology

Background:

• Low-dose aspirin is widely used for cardiovascular prevention.
• Its precise effects on platelet function, beyond thromboxane inhibition, require further elucidation.
• Understanding aspirin's impact on platelet secretion is vital for assessing its clinical efficacy.

Purpose of the Study:

• To investigate the effects of low-dose aspirin on platelet aggregation and dense granule secretion.
• To determine aspirin's impact on thromboxane formation inhibition.
• To explore potential modifications of platelet function inhibition by iloprost and linsidomine.

Main Methods:

• 15 healthy males received 40 mg/day aspirin for 8 days.
• Platelet function, thromboxane B(2) (TXB(2)), and 6-oxo-PGF(1α) excretion were measured ex vivo.
• Platelet secretion was assessed using collagen, ADP, and thrombin as stimuli.

Main Results:

• Aspirin significantly reduced urinary TXB(2) excretion by 65%, confirming cyclooxygenase inhibition.
• Collagen-induced platelet secretion (ATP, 5-HT) was only minimally inhibited (20%).
• Thrombin-induced secretion remained unaffected by aspirin.

Conclusions:

• Platelet secretion stimulated by potent agonists like collagen and thrombin is largely independent of the cyclooxygenase pathway.
• Measuring serum thromboxane levels may not fully capture aspirin's effect on platelet activation in all clinical settings.
• These findings are relevant for understanding platelet activation in conditions like carotid stenosis and atherosclerotic plaques.